Drug pricing for hepatitis B and C in Australia and Japan
Open Access
- 23 September 2025
- journal article
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 102118
Abstract
No abstract availableFunding Information
- National Health and Medical Research Council (APP1107178)
- National Health and Medical Research Council (APP2001692)
- National Health and Medical Research Council (APP1053206)
- National Health and Medical Research Council (APP1196492)
- National Health and Medical Research Council (APP1108422)
- Australasian Gastro-Intestinal Trials Group
- University of Sydney
- Cancer Institute NSW
This publication has 5 references indexed in Scilit:
- A global comparison of hepatitis B & C drug pricingAnnals of Hepatology, 2025
- Controlling Spending For Health Care And Long-Term Care: Japan’s Experience With A Rapidly Aging SocietyHealth Affairs, 2023
- Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 updateHepatology Research, 2020
- An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical PrinciplesJournal of Law, Medicine & Ethics, 2020
- Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in AustraliaJournal of Public Health Policy, 2008